RNACCartesian Therapeutics, Inc.

Nasdaq www.cartesiantherapeutics.com


$ 21.19 $ -0.69 (-3.16 %)    

Friday, 10-May-2024 15:59:33 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 21.17
$ 21.78
$ 0.00 x 0
$ 21.31 x 100
$ 21.10 - $ 22.30
$ 11.67 - $ 42.60
54,832
na
114.61M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-17-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-12-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-15-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-28-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-cartesian-therapeutics-maintains-54-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $54...

 needham-reiterates-buy-on-cartesian-therapeutics-maintains-42-price-target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

 hc-wainwright--co-maintains-buy-on-cartesian-therapeutics-adjusts-price-target-to-54

HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy, adjusts target to...

 leerink-partners-initiates-coverage-on-cartesian-therapeutics-with-outperform-rating-announces-price-target-of-39

Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating an...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 cartesian-therapeutics-rare-disease-candidate-shows-long-lasting-benefit-over-argenxs-vyvgart-analyst-initiates-with-buy

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising ant...

 needham-reiterates-buy-on-cartesian-therapeutics-maintains-42-price-target

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

 needham-initiates-coverage-on-cartesian-therapeutics-with-buy-rating-announces-price-target-of-42

Needham analyst Gil Blum initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Buy rating and announces Price Ta...

 cartesian-therapeutics-announces-approval-of-conversion-of-series-a-convertible-preferred-stock-and-plans-to-effect-1-for-30-reverse-stock-split-effective-after-the-closing-of-trading-hours-on-april-4-2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell...

 liveperson-and-2-other-stocks-under-2-insiders-are-buying

The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their conf...

 hc-wainwright--co-reiterates-buy-on-cartesian-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $2 ...

 on-march-8-cartesian-therapeutics-received-notice-from-audentes-therapeutics-of-termination-of-license-and-development-agreement-dated-jan-8-2023

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION